Trial Profile
GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Vitamin K antagonists
- Indications Atrial fibrillation; Myocardial infarction; Pulmonary embolism; Stroke; Thromboembolism; Transient ischaemic attacks
- Focus Adverse reactions; Therapeutic Use
- Acronyms GLORIA-AF
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
- 01 Jan 2024 Results of pooled analysis from NCT01468701, NCT01671007 and NCT01937377; evaluating the predictive ability of the 2MACE score published in the Journal of Thrombosis and Thrombolysis
- 01 Jan 2024 Results demonstrating antithrombotic effect of dabigatran and vitamin K antagonist in Patients with Atrial Fibrillation, published in the American Journal of Therapeutics
- 01 Sep 2022 Results assessing the effects of early atrial fibrillation ablation compared to medical therapy in GLORIA-AF registries, published in the Clinical Research in Cardiology